Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P Van Dreden

Showing results (21-30 of 27) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 27 results.
Thrombosis Research|May 11, 2016
OC-03 - Modelisation of the procoagulant properties of cancer cells and their capacity to alter the antithrombotic efficiency of LMWHs and specific inhibitors of factor XaG T Gerotziafas, A Rousseau, P van Dreden, et al.
Lancet (London, England)|March 21, 1992
Homozygous protein C deficiency with late onset and recurrent coumarin-induced skin necrosisJ Conard, M H Horellou, P van Dreden, et al.
Thrombosis and Haemostasis|November 3, 1998
Low levels of protein S activity in factor V depleted plasma used in APC resistance testM S Samama, I Gouin-Thibault, M Trossaert, et al.
Thrombosis and Haemostasis|March 4, 1999
The factor V gene A4070G mutation and the risk of venous thrombosisM Alhenc-Gelas, V Nicaud, S Gandrille, et al.
Archives Des Maladies Du Coeur Et Des Vaisseaux|October 1, 1986
[Tissue plasminogen activator (t-PA) in myocardial infarction. Biological aspects]M Samama, E Verdy, J Conard, et al.
Thrombosis Research|May 11, 2016
PO-53 - Prospective evaluation of risk assessment models and biological markers of hypercoagulability for the identification of high VTE risk patients with lung adenocarcinoma. The ROADMAP studyP Boura, I Evmorfiadis, A Rousseau, et al.
Blood Coagulation & Fibrinolysis : an International Journal in Haemostasis and Thrombosis|August 5, 1998
Assessment of activated protein C resistance using a new and rapid venom-based test: STA Staclot APC-RE Oger, C Leroyer, B Mercier, et al.
Pageof 3

Showing results (21-30 of 27) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 27 results.
Thrombosis Research|May 11, 2016
OC-03 - Modelisation of the procoagulant properties of cancer cells and their capacity to alter the antithrombotic efficiency of LMWHs and specific inhibitors of factor XaG T Gerotziafas, A Rousseau, P van Dreden, et al.
Lancet (London, England)|March 21, 1992
Homozygous protein C deficiency with late onset and recurrent coumarin-induced skin necrosisJ Conard, M H Horellou, P van Dreden, et al.
Thrombosis and Haemostasis|November 3, 1998
Low levels of protein S activity in factor V depleted plasma used in APC resistance testM S Samama, I Gouin-Thibault, M Trossaert, et al.
Thrombosis and Haemostasis|March 4, 1999
The factor V gene A4070G mutation and the risk of venous thrombosisM Alhenc-Gelas, V Nicaud, S Gandrille, et al.
Archives Des Maladies Du Coeur Et Des Vaisseaux|October 1, 1986
[Tissue plasminogen activator (t-PA) in myocardial infarction. Biological aspects]M Samama, E Verdy, J Conard, et al.
Thrombosis Research|May 11, 2016
PO-53 - Prospective evaluation of risk assessment models and biological markers of hypercoagulability for the identification of high VTE risk patients with lung adenocarcinoma. The ROADMAP studyP Boura, I Evmorfiadis, A Rousseau, et al.
Blood Coagulation & Fibrinolysis : an International Journal in Haemostasis and Thrombosis|August 5, 1998
Assessment of activated protein C resistance using a new and rapid venom-based test: STA Staclot APC-RE Oger, C Leroyer, B Mercier, et al.
Pageof 3